Skip to content

Design and Development of a Mobile App to Improve Adherence to Pre-exposure Prophylaxis in Men Who Have Sex With Men

Design and Development of a Mobile App to Improve Adherence to Pre-exposure Prophylaxis in Men Who Have Sex With Men: A Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04248790
Enrollment
35
Registered
2020-01-30
Start date
2020-05-25
Completion date
2020-10-23
Last updated
2020-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, Pre-Exposure Prophylaxis

Brief summary

This study is testing feasibility and acceptability of a theoretically based mobile application (app), UPrEPU, to increase adherence to pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) to prevent human immunodeficiency virus (HIV).

Detailed description

This study aims to develop an effective mobile application (app), UPrEPU to recognize the factors and decisions that affect PrEP adherence in high-risk populations to improve PrEP adherence. Key components of the app include a sex/PrEP diary using ecological momentary assessment to facilitate accurate data collection; PrEP taking reminder; HIV and sexually transmitted infections (STI) testing information and reminders; HIV and PrEP information and videos; geo-location. After eligible PrEP candidates agree to participate in the study, we will ask participants to install the app. Then, we will begin to collect their sexual diary and PrEP taking log via ecological momentary assessment. Participants will also complete monthly assessments. The monthly follow-up will test HIV/STI and drug concentration. The participants will be interviewed for difficulties when they use our app and giving feedback on it.

Interventions

BEHAVIORALmobile app to improve adherence to PrEP self-management

Access to the mobile app which includes the sex and PrEP diary, information on HIV/STI testing, PrEP reminders and geo-location features.

Sponsors

National Cheng-Kung University Hospital
CollaboratorOTHER
Taipei Veterans General Hospital, Taiwan
CollaboratorOTHER_GOV
National Tsing Hua University
CollaboratorOTHER
National Cheng Kung University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
20 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* Male. * Aged 20 or above. * Resides in Taiwan and able to understand, read, and speak Mandarin Chinese. * Remains HIV negative prior to and during the study period. * The results of the laboratory tests are eligible to initiate PrEP. * Currently taking PrEP or willing to initiate PrEP. * Reports having 4 times or above anal sex with men in the past month. * Owns an Android or Apple operating system (iOS) smartphone and willing to download the study app. * Willing to wear the device we provided during the study period.

Exclusion criteria

* With abnormal kidney function (creatinine clearance rate ≦ 60 mL/minute). * Currently on medication that might interact with PrEP, such as drugs contain lamivudine in the pre-PrEP assessment.

Design outcomes

Primary

MeasureTime frameDescription
Usability4 monthsScores on system usability scale (SUS) for this app at the first month and the fourth month.
Feasibility: data based on the app analytics4 months1. Frequency of app log-in; 2. Use of app components such as PrEP-taking and sex behavior reports; 3. Duration of app use
Efficacy of adherence monitoring4 monthsMeasuring the Tenofovir (TDF) and Emtricitabine (FTC) drug concentration in dried blood spot (DBS) samples to compare with self-report data

Secondary

MeasureTime frameDescription
Feasibility: data from qualitative interviews4 months1. any technical challenges participants may have encountered; 2. recommendations for the app improvement; 3. users' satisfaction and comfort in using this app

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026